ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Glioblastoma Multiforme
Interventions
DEVICE

BBB Disruption with Chemotherapy Arm

The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.

Trial Locations (1)

03722

Severance Hospital, Yonsei University Health System, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

InSightec

INDUSTRY